Global Recombinant Vaccines Market

Recombinant Vaccines Market Size, Share, Growth Analysis, By End user(Pediatric and Adult), By Distribution channel(Hospitals and Vaccination centers), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35A2787 | Region: Global | Published Date: July, 1990
Pages: 219 |Tables: 59 |Figures: 64

Recombinant Vaccines Market Insights

Global Recombinant Vaccines Market size was valued at USD 9.02 Billion in 2022 and is poised to grow from USD 10.05 Billion in 2023 to USD 23.83 Billion by 2031, at a CAGR of 11.40% during the forecast period (2024-2031).

Early vaccines relied heavily on exposure strategies, often involving the attenuation or inactivation of pathogens. But the advent of genetic engineering, genomics and recombinant DNA technologies has revolutionized vaccine development.

Recently, these new approaches have paved the way for newly developed vaccines in the market. Unlike traditional methods, these vaccines are developed under laboratory conditions using genetic screening techniques to eliminate the risk associated with infectious diseases. This not only ensures the effectiveness of the vaccines but also prioritizes safety in the vaccination process. The intersection of genetic engineering and vaccine development represents a significant leap forward, allowing for a more precise and targeted approach to immunization.

Market Snapshot - 2024-2031

Global Market Size

USD 9.02 Billion

Largest Segment

Adults

Fastest Growth

Adults

Growth Rate

11.40% CAGR

Global Recombinant Vaccines Market ($ Bn)
Country Share for North america Region (%)

To get more reports on the above market click here to Buy The Report

Recombinant Vaccines Market Segmental Analysis

On the basis of indication, the market is classified into human papillomavirus, meningococcal and others. On the basis of end user, the market is bifurcated into pediatric and adult. On the basis of distribution channel, the market is classified into hospitals and vaccination centers. Region wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, Australia, India, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Analysis by Indication

The Human Papillomavirus (HPV) segment is poised to exhibit a substantial growth share throughout the forecast period. This distinctive name accounts for the increasing prevalence of human papillomavirus-associated infections in the general population. Continuous increases in health spending, and concerted efforts and initiatives from global authorities such as the United Nations International Children’s Emergency Fund (UNICEF), the World Health Organization (WHO), and Pan American Public Health Organization (PAHO) have been instrumental in increasing the supply of vaccines targeting HPV.

The meningococcal segment plays an important role in the recombinant vaccines market, contributing significantly to the prevention of meningococcal infections. Meningococcal diseases caused by Neisseria meningitidis virus are a major public health problem due to potential early onset and severe consequences, including meningitis and septicemia. Recombinant vaccines targeting meningococcal species leading to technological advances in combating these diseases. They also provide an effective tool. Using recombinant DNA technology, these compounds can stimulate robust immune responses without the use of live bacteria, increasing safety and efficacy.

Analysis by End-Users

The adult segment is expected to account for significant growth throughout the forecast period, driven by several factors. The high rate of older patients with infectious diseases is an important indicator of this trend. Rising demand for recombinant vaccines, coupled with increased manufacturing capacity to meet unmet needs, further supports the dominance of the adult segment. Furthermore, vaccines and re-efficacy of various disease control mixes plays an important role in enhancing the growth of this segment.

The pediatric segment plays an important role in the recombinant vaccines market, being a keystone in the prevention of various infectious diseases affecting children. Recombinant vaccines designed for child use use advanced biotechnology techniques for vaccination safe and effective solutions. These vaccines aim to protect children against certain diseases such as measles, mumps, rubella, and influenza Using recombinant DNA technology, these vaccines are precise with a targeted approach for immune stimulation without the use of live bacteria.

Global Recombinant Vaccines Market By End User, 2022 (%)

To get detailed analysis on other segments, Request For Free Sample Report

Recombinant Vaccines Market Regional Insights

North America emerged as the dominant region in the recombinant vaccines market, a trend expected to continue throughout the forecast period. The region dominates due to a combination of factors, such as high prevalence of chronic diseases, a significantly higher number of players, and higher vaccination rates offered. stimulating a dynamic approach to vaccination strategies.

Asia-Pacific is poised to record the highest annual growth rate (CAGR) during the analyzed period, driven by several primary factors. The presence of densely populated countries such as India and China contributes significantly to diseases causing widespread infection in the region. Furthermore, rising product launches and other factors being adopted by market players influence the market growth in Asia-Pacific.

Global Recombinant Vaccines Market By Region, 2024-2031
  • Largest
  • Fastest

To know more about the market opportunities by region and country, click here to
Buy The Complete Report

Recombinant Vaccines Market Dynamics

Drivers

Increase in Sales of Genetically Modified Vaccines

  • An instrumental driver of market growth is the extensive utilization of recombinant properties, which significantly enhances the efficacy and safety of vaccines administered to patients. The inherent advantages of recombinant technology enable the rapid and large-scale production of vaccines, mitigating the risk of shortages in supply. Moreover, these vaccines are devoid of infectious viral particles, minimizing the potential for infection and rendering them safe for individuals with compromised immune systems. The notable benefits associated with recombinant vaccines have spurred deliberate efforts among manufacturers to focus on the development of innovative products targeting viral diseases. This endeavor involves leveraging advanced DNA technology, genomics, and other cutting-edge biotechnology techniques, collectively contributing to the evolution of more effective and safer vaccines.

Restraints

High Cost Associated with Per Dose Vaccine

  • Despite the heightened prevalence of both chronic and infectious diseases, the adoption of vaccines is impeded by various factors, with the high cost per dose being a significant hindrance. While international organizations are diligently contributing to the global vaccination effort by supplying millions of doses across diverse regions, the elevated cost of vaccination remains a barrier for many populations. Despite concerted efforts to reach every corner of the world, certain regions continue to face challenges in vaccine accessibility due to the associated high costs.

Request Free Customization of this report to help us to meet your business objectives.

Recombinant Vaccines Market Competitive Landscape

The competitive environment of the global Recombinant Vaccines market is dynamic and characterized by the presence of a mix of well-established brands, emerging players, and niche producers. Innovation is a key competitive factor. Leading brands invest in research and development to introduce new flavors, packaging formats, and health-focused variations to cater to changing consumer preferences. They often set the trends in the industry.

Top Player’s Company Profiles

  • AstraZeneca Plc.
  • Dynavax Technologies Corporation
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline Plc.
  • Johnson & Johnson, Merck & Co. Inc.
  • Novavax, Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Serum Institute of India Pvt. Ltd.

Recent Developments

  • In February 2024, SII announced positive phase 3 trial data for their R21/Matrix-M™ malaria vaccine. This recombinant vaccine received a WHO recommendation in October 2023, paving the way for global rollout to fight malaria, especially in Africa.
  • In September 2021, Serum of India unveiled plans to launch at least one vaccine every three months, starting with AstraZeneca's licensed vaccine Covishield The project reflects the company's commitment to develop a variety of strategies to contribute to global immunization efforts.
  • In September 2020, the Serum Institute of India partnered with the Bill and Melinda Gates Foundation. And it aims to develop and distribute more than 100 million more safe and effective COVID-19 vaccines. This collaborative effort constitutes the Gavi COVAX AMC, an important tool within the Covax portfolio, specifically designed to provide vaccine access to low- and middle-income countries (LMICs).

Recombinant Vaccines Key Market Trends

  • The increasing incidence of infectious diseases worldwide has led to an urgent demand for effective vaccines. This urgency is compounded by the high susceptibility of elderly and pediatric nurses to serious diseases, and rapid vaccination efforts are needed worldwide. International organizations such as UNICEF and PAHO have played a key role in the delivery of millions of doses to countries facing emergency needs that supported the vaccine stoppage . The efficient procurement of vaccine quantities by these organizations has greatly reduced the spread of many diseases and strengthened the population’s resistance to all these health threats.

Recombinant Vaccines Market SkyQuest Analysis

SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyzes the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research. Major pharmaceutical companies including GSK and Merck invest heavily in research and development (R&D) to advance genetically modified vaccines for example GSK has an extensive pipeline that includes hepatitis B, meningococcal B, papillomavirus, respiratory syncytial virus infection, rotavirus etc. This leads to innovations targeted at various infection candidates. A new effective commitment to address infectious diseases lies in a focused approach to vaccine introduction. The concerted efforts of key market players including GSK and Merck are crucial in boosting the growth of the global market, which is expected to register a compound annual growth rate (CAGR) during the analyzed period.

Report Metric Details
Market size value in 2022 USD 9.02 Billion
Market size value in 2031 USD 23.83 Billion
Growth Rate 11.40%
Base year 2023
Forecast period 2024-2031
Forecast Unit (Value) USD Billion
Segments covered
  • End user
    • Pediatric and Adult
  • Distribution channel
    • Hospitals and Vaccination centers
Regions covered North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA)
Companies covered
  • AstraZeneca Plc.
  • Dynavax Technologies Corporation
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline Plc.
  • Johnson & Johnson, Merck & Co. Inc.
  • Novavax, Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Serum Institute of India Pvt. Ltd.
Customization scope

Free report customization with purchase. Customization includes:-

  • Segments by type, application, etc
  • Company profile
  • Market dynamics & outlook
  • Region

To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.

Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share

Table Of Content

Executive Summary

Market overview

  • Exhibit: Executive Summary – Chart on Market Overview
  • Exhibit: Executive Summary – Data Table on Market Overview
  • Exhibit: Executive Summary – Chart on Recombinant Vaccines Market Characteristics
  • Exhibit: Executive Summary – Chart on Market by Geography
  • Exhibit: Executive Summary – Chart on Market Segmentation
  • Exhibit: Executive Summary – Chart on Incremental Growth
  • Exhibit: Executive Summary – Data Table on Incremental Growth
  • Exhibit: Executive Summary – Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • SWOT Analysis

KEY MARKET INSIGHTS

  • Technology Analysis
    • (Exhibit: Data Table: Name of technology and details)
  • Pricing Analysis
    • (Exhibit: Data Table: Name of technology and pricing details)
  • Supply Chain Analysis
    • (Exhibit: Detailed Supply Chain Presentation)
  • Value Chain Analysis
    • (Exhibit: Detailed Value Chain Presentation)
  • Ecosystem Of the Market
    • Exhibit: Parent Market Ecosystem Market Analysis
    • Exhibit: Market Characteristics of Parent Market
  • IP Analysis
    • (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
  • Trade Analysis
    • (Exhibit: Data Table: Import and Export data details)
  • Startup Analysis
    • (Exhibit: Data Table: Emerging startups details)
  • Raw Material Analysis
    • (Exhibit: Data Table: Mapping of key raw materials)
  • Innovation Matrix
    • (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
  • Pipeline product Analysis
    • (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
  • Macroeconomic Indicators

COVID IMPACT

  • Introduction
  • Impact On Economy—scenario Assessment
    • Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
  • Revised Market Size
    • Exhibit: Data Table on Recombinant Vaccines Market size and forecast 2021-2027 ($ million)
  • Impact Of COVID On Key Segments
    • Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
  • COVID Strategies By Company
    • Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • Regulatory Landscape
    • Exhibit: Data Table on regulation from different region
  • SWOT Analysis
  • Porters Analysis
    • Competitive rivalry
      • Exhibit: Competitive rivalry Impact of key factors, 2021
    • Threat of substitute products
      • Exhibit: Threat of Substitute Products Impact of key factors, 2021
    • Bargaining power of buyers
      • Exhibit: buyers bargaining power Impact of key factors, 2021
    • Threat of new entrants
      • Exhibit: Threat of new entrants Impact of key factors, 2021
    • Bargaining power of suppliers
      • Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
  • Skyquest special insights on future disruptions
    • Political Impact
    • Economic impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Market Size by Region

  • Chart on Market share by geography 2021-2027 (%)
  • Data Table on Market share by geography 2021-2027(%)
  • North America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • USA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Canada
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Europe
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Germany
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Spain
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • France
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • UK
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Europe
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Asia Pacific
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • China
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • India
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Japan
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Korea
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Asia Pacific
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Latin America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Brazil
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of South America
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Middle East & Africa (MEA)
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • GCC Countries
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Africa
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of MEA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

  • Competitive Landscape
    • Total number of companies covered
      • Exhibit: companies covered in the report, 2021
    • Top companies market positioning
      • Exhibit: company positioning matrix, 2021
    • Top companies market Share
      • Exhibit: Pie chart analysis on company market share, 2021(%)

Methodology

For the Recombinant Vaccines Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:

1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.

2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Recombinant Vaccines Market.

3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.

4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.

Analyst Support

Customization Options

With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Recombinant Vaccines Market:

Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.

Regional Analysis: Further analysis of the Recombinant Vaccines Market for additional countries.

Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.

Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.

Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.

Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.

Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.

Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Recombinant Vaccines Market size was valued at USD 9.02 Billion in 2022 and is poised to grow from USD 10.05 Billion in 2023 to USD 23.83 Billion by 2031, at a CAGR of 11.40% during the forecast period (2024-2031).

The competitive environment of the Recombinant Vaccines market is dynamic and characterized by the presence of a mix of well-established brands, emerging players, and niche producers. Innovation is a key competitive factor. Leading brands invest in research and development to introduce new flavors, packaging formats, and health-focused variations to cater to changing consumer preferences. They often set the trends in the industry. 'AstraZeneca Plc.', 'Dynavax Technologies Corporation', 'Emergent BioSolutions Inc.', 'GlaxoSmithKline Plc.', 'Johnson & Johnson, Merck & Co. Inc.', 'Novavax, Inc.', 'Pfizer Inc.', 'Sanofi S.A.', 'Serum Institute of India Pvt. Ltd.'

An instrumental driver of market growth is the extensive utilization of recombinant properties, which significantly enhances the efficacy and safety of vaccines administered to patients. The inherent advantages of recombinant technology enable the rapid and large-scale production of vaccines, mitigating the risk of shortages in supply. Moreover, these vaccines are devoid of infectious viral particles, minimizing the potential for infection and rendering them safe for individuals with compromised immune systems. The notable benefits associated with recombinant vaccines have spurred deliberate efforts among manufacturers to focus on the development of innovative products targeting viral diseases. This endeavor involves leveraging advanced DNA technology, genomics, and other cutting-edge biotechnology techniques, collectively contributing to the evolution of more effective and safer vaccines.

The increasing incidence of infectious diseases worldwide has led to an urgent demand for effective vaccines. This urgency is compounded by the high susceptibility of elderly and pediatric nurses to serious diseases, and rapid vaccination efforts are needed worldwide. International organizations such as UNICEF and PAHO have played a key role in the delivery of millions of doses to countries facing emergency needs that supported the vaccine stoppage . The efficient procurement of vaccine quantities by these organizations has greatly reduced the spread of many diseases and strengthened the population’s resistance to all these health threats.

North America emerged as the dominant region in the recombinant vaccines market, a trend expected to continue throughout the forecast period. The region dominates due to a combination of factors, such as high prevalence of chronic diseases, a significantly higher number of players, and higher vaccination rates offered. stimulating a dynamic approach to vaccination strategies.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Recombinant Vaccines Market

Product ID: SQMIG35A2787

$5,300
BUY NOW GET FREE SAMPLE